AAAAAA

   
Results: 1-9 |
Results: 9
LEUKOTRIENE SYNTHESIS INHIBITORS OF THE QUINOLINE TYPE - PARAMETERS FOR THE OPTIMIZATION OF EFFICACY
Authors: MATZKE M BECKERMANN B FRUCHTMANN R FUGMANN B GARDINER PJ GOOSSENS J HATZELMANN A JUNGE B KELDENICH J KOHLSDORFER C MOHRS KH MULLERPEDDINGHAUS R RADDATZ S
Citation: M. Matzke et al., LEUKOTRIENE SYNTHESIS INHIBITORS OF THE QUINOLINE TYPE - PARAMETERS FOR THE OPTIMIZATION OF EFFICACY, European journal of medicinal chemistry, 30, 1995, pp. 441-451
MODE OF ACTION OF THE LEUKOTRIENE SYNTHESIS (FLAP) INHIBITOR BAY-X-1005 - IMPLICATIONS FOR BIOLOGICAL REGULATION OF 5-LIPOXYGENASE
Authors: HATZELMANN A FRUCHTMANN R MOHRS KH RADDATZ S MATZKE M PLEISS U KELDENICH J MULLERPEDDINGHAUS R
Citation: A. Hatzelmann et al., MODE OF ACTION OF THE LEUKOTRIENE SYNTHESIS (FLAP) INHIBITOR BAY-X-1005 - IMPLICATIONS FOR BIOLOGICAL REGULATION OF 5-LIPOXYGENASE, Agents and actions, 43(1-2), 1994, pp. 64-68
ROLE OF 5-LIPOXYGENASE-ACTIVATING PROTEIN IN THE REGULATION OF 5-LIPOXYGENASE ACTIVITY IN HUMAN NEUTROPHILS
Authors: KAST R FRUCHTMANN R KUPFERSCHMIDT R MOHRS KH RADDATZ S MULLERPEDDINGHAUS R HATZELMANN A
Citation: R. Kast et al., ROLE OF 5-LIPOXYGENASE-ACTIVATING PROTEIN IN THE REGULATION OF 5-LIPOXYGENASE ACTIVITY IN HUMAN NEUTROPHILS, Agents and actions, 41, 1994, pp. 30000166-30000168
-2-[4-(QUINOLIN-2-YL-METHOXY)PHENYL]-2-CYCLOPENTYL ACETIC-ACID (BAY X1005), A POTENT LEUKOTRIENE SYNTHESIS INHIBITOR - EFFECTS ON ANTI-LGE CHALLENGE IN HUMAN AIRWAYS
Authors: GORENNE I LABAT C GASCARD JP NOREL X MULLERPEDDINGHAUS R MOHRS KH TAYLOR WA GARDINER PJ BRINK C
Citation: I. Gorenne et al., -2-[4-(QUINOLIN-2-YL-METHOXY)PHENYL]-2-CYCLOPENTYL ACETIC-ACID (BAY X1005), A POTENT LEUKOTRIENE SYNTHESIS INHIBITOR - EFFECTS ON ANTI-LGE CHALLENGE IN HUMAN AIRWAYS, The Journal of pharmacology and experimental therapeutics, 268(2), 1994, pp. 868-872
CA2-STIMULATED SECRETION OF AZUROPHIL GRANULES IN HUMAN POLYMORPHONUCLEAR LEUKOCYTES IS LARGELY MEDIATED BY ENDOGENOUSLY FORMED LEUKOTRIENEB-4( IONOPHORE A23187)
Authors: HATZELMANN A FRUCHTMANN R MOHRS KH RADDATZ S MULLERPEDDINGHAUS R
Citation: A. Hatzelmann et al., CA2-STIMULATED SECRETION OF AZUROPHIL GRANULES IN HUMAN POLYMORPHONUCLEAR LEUKOCYTES IS LARGELY MEDIATED BY ENDOGENOUSLY FORMED LEUKOTRIENEB-4( IONOPHORE A23187), Biochemical pharmacology, 48(1), 1994, pp. 31-39
INVERSELY-CORRELATED INHIBITION OF HUMAN 5-LIPOXYGENASE ACTIVITY BY BAY X1005 AND OTHER QUINOLINE DERIVATIVES IN INTACT-CELLS AND A CELL-FREE SYSTEM - IMPLICATIONS FOR THE FUNCTION OF 5-LIPOXYGENASE ACTIVATINGPROTEIN
Authors: HATZELMANN A GOOSSENS J FRUCHTMANN R MOHRS KH RADDATZ S MULLERPEDDINGHAUS R
Citation: A. Hatzelmann et al., INVERSELY-CORRELATED INHIBITION OF HUMAN 5-LIPOXYGENASE ACTIVITY BY BAY X1005 AND OTHER QUINOLINE DERIVATIVES IN INTACT-CELLS AND A CELL-FREE SYSTEM - IMPLICATIONS FOR THE FUNCTION OF 5-LIPOXYGENASE ACTIVATINGPROTEIN, Biochemical pharmacology, 47(12), 1994, pp. 2259-2268
BAY-X1005, A NEW SELECTIVE INHIBITOR OF LEUKOTRIENE SYNTHESIS - PHARMACOLOGY AND PHARMACOKINETICS
Authors: MULLERPEDDINGHAUS R FRUCHTMANN R AHR HJ BECKERMANN B BUHNER K FUGMANN B JUNGE B MATZKE M KOHLSDORFER C RADDATZ S THEISENPOPP P MOHRS KH
Citation: R. Mullerpeddinghaus et al., BAY-X1005, A NEW SELECTIVE INHIBITOR OF LEUKOTRIENE SYNTHESIS - PHARMACOLOGY AND PHARMACOKINETICS, Journal of lipid mediators, 6(1-3), 1993, pp. 245-248
IN-VITRO PHARMACOLOGY OF BAY-X1005, A NEW INHIBITOR OF LEUKOTRIENE SYNTHESIS
Authors: FRUCHTMANN R MOHRS KH HATZELMANN A RADDATZ S FUGMANN B JUNGE B HORSTMANN H MULLERPEDDINGHAUS R
Citation: R. Fruchtmann et al., IN-VITRO PHARMACOLOGY OF BAY-X1005, A NEW INHIBITOR OF LEUKOTRIENE SYNTHESIS, Agents and actions, 38(3-4), 1993, pp. 188-195
BAY X1005, A NEW INHIBITOR OF LEUKOTRIENE SYNTHESIS - IN-VIVO INFLAMMATION PHARMACOLOGY AND PHARMACOKINETICS
Authors: MULLERPEDDINGHAUS R KOHLSDORFER C THEISENPOPP P FRUCHTMANN R PERZBORN E BECKERMANN B BUHNER K AHR HJ MOHRS KH
Citation: R. Mullerpeddinghaus et al., BAY X1005, A NEW INHIBITOR OF LEUKOTRIENE SYNTHESIS - IN-VIVO INFLAMMATION PHARMACOLOGY AND PHARMACOKINETICS, The Journal of pharmacology and experimental therapeutics, 267(1), 1993, pp. 51-57
Risultati: 1-9 |